Studies from University of Melbourne Yield New Data on Aldosterone Receptor Antagonists (Effect of spironolactone and cyproterone acetate on breast growth in transgender people: a randomized clinical trial).

A recent clinical trial conducted by the University of Melbourne aimed to assess the effect of anti-androgens on breast development in transgender individuals. The trial compared the use of cyproterone acetate and spironolactone as anti-androgens alongside estradiol therapy. The results showed no significant difference in breast development between the two groups, but cyproterone acetate was more effective in suppressing serum testosterone levels. The researchers concluded that the choice of anti-androgen should be based on clinician and patient preference, taking into consideration side effects. Further research is needed to optimize breast development in transgender individuals. [Extracted from the article]

Copyright of Women's Health Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)